Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$45.25 USD

45.25
10,148,972

+0.55 (1.23%)

Updated Apr 26, 2024 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for BMY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 12,280 9,253 16,966 15,831 15,393
Receivables 10,921 9,886 9,369 8,501 7,685
Notes Receivable 0 0 0 0 0
Inventories 2,662 2,339 2,095 2,074 4,293
Other Current Assets 5,907 5,795 4,832 3,786 1,983
Total Current Assets 31,770 27,273 33,262 30,192 29,354
Net Property & Equipment 6,646 6,255 6,049 5,886 6,252
Investments & Advances 364 0 0 433 767
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2,768 1,344 1,439 1,161 510
Intangibles 48,241 57,008 63,029 73,790 86,457
Deposits & Other Assets 5,370 4,940 5,535 7,019 6,604
Total Assets 95,159 96,820 109,314 118,481 129,944
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3,259 3,040 2,949 2,713 2,445
Current Portion Long-Term Debt 3,119 4,264 4,948 2,340 3,346
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 15,884 14,586 13,971 14,027 12,513
Total Current Liabilities 22,262 21,890 21,868 19,080 18,304
Mortgages 0 0 0 0 0
Deferred Taxes/Income 338 2,166 4,501 5,407 6,454
Convertible Debt 0 0 0 0 0
Long-Term Debt 36,653 35,056 39,605 48,336 43,387
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6,421 6,590 7,334 7,776 10,101
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 65,674 65,702 73,308 80,599 78,246
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 292 292 292 292 292
Capital Surplus 45,684 45,165 44,361 44,325 43,709
Retained Earnings 28,766 25,503 23,820 21,281 34,474
Other Equity -1,491 -1,224 -1,208 -1,779 -1,420
Treasury Stock 43,766 38,618 31,259 26,237 25,357
Total Shareholder's Equity 29,485 31,118 36,006 37,882 51,698
Total Liabilities & Shareholder's Equity 95,159 96,820 109,314 118,481 129,944
Total Common Equity 29,485 31,118 36,006 37,882 51,698
Shares Outstanding 2,034.70 2,126.10 2,219.60 2,262.60 2,228.00
Book Value Per Share 14.49 14.64 16.22 16.74 23.20

Fiscal Year End for Bristol Myers Squibb Company falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 12,280 7,685 8,730 9,269
Receivables NA 10,921 10,304 10,112 10,054
Notes Receivable NA 0 0 0 0
Inventories NA 2,662 2,436 2,364 2,605
Other Current Assets NA 5,907 7,207 6,868 5,158
Total Current Assets NA 31,770 27,632 28,074 27,086
Net Property & Equipment NA 6,646 6,481 6,355 6,279
Investments & Advances NA 364 325 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 2,768 1,514 1,572 1,317
Intangibles NA 48,241 50,097 52,466 54,731
Deposits & Other Assets NA 5,370 5,214 5,022 4,868
Total Assets NA 95,159 91,263 93,489 94,281
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 3,259 2,813 3,069 3,194
Current Portion Long-Term Debt NA 3,119 5,467 3,020 2,752
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 15,884 15,182 14,061 13,139
Total Current Liabilities NA 22,262 23,462 20,150 19,085
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 338 399 751 1,568
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 36,653 32,137 34,656 35,078
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 6,203 5,902 6,664
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 65,674 62,201 61,459 62,395
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 292 292 292 292
Capital Surplus NA 45,684 44,849 45,299 45,140
Retained Earnings NA 28,766 28,218 27,449 26,568
Other Equity NA -1,491 -1,222 -1,330 -1,306
Treasury Stock NA 43,766 43,075 39,680 38,808
Total Shareholder's Equity NA 29,485 29,062 32,030 31,886
Total Liabilities & Shareholder's Equity NA 95,159 91,263 93,489 94,281
Total Common Equity 0 29,485 29,062 32,030 31,886
Shares Outstanding 2,026.70 2,034.70 2,034.70 2,089.10 2,100.80
Book Value Per Share 0.00 14.49 14.28 15.33 15.18